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The uterine endometrium is exquisitely 
sensitive to hormones, in particular estrogen 
and progesterone and to a lesser extent 
androgens and glucocorticoids. These 
hormones tightly regulate the complex 
functioning of the female reproductive tract 
and are intimately involved in controlling the 
growth, development, and remodeling of 
reproductive tissues as well as the cyclic 
changes that occur during the menstrual 
cycle. Steroids function by binding to nuclear 
receptor proteins that act as transcription 
factors to modulate the expression of genes, 
though many non-genomic effects for 
steroids have also been described. An 
imbalance of the hormones leads to cancer. 
In particular, endometrial carcinogenesis is 
related to overexposure to estrogen that is 
not balanced by the differentiating effects of 
progesterone and potentially other steroid 
hormones, including androgens and 
glucocorticoids. This review summarizes 
steroid hormone action in the endometrium, 
describes the relative localization of 
hormone receptors in the normal 
endometrium and in endometrial cancer, 
and highlights key clinical trials that have 
attempted to restore the balance of 
hormones and thus prevent recurrence of 
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The uterine endometrium is 
exquisitely sensitive to hormones. 
The best studied and most relevant 
steroids that participate in 
endometrial cellular processes are 
the estrogens and progestins. These 
hormones tightly regulate the 
complex functioning of the female 
reproductive tract. Both hormones 
are intimately involved in controlling 
the growth, development, and 
remodeling of reproductive tissues 
as well as for the cyclic changes that 
occur during the menstrual cycle. 
Estradiol is the principal estrogen, 
although both estrone (a precursor to 
estradiol) and estriol (a metabolic 
product of estradiol) also have 
estrogenic actions. The most 
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relevant naturally occurring 
progestins are progesterone and its 
17-hydroxy derivative. These 
steroids function by binding to 
nuclear receptor proteins that act as 
transcription factors to modulate the 
expression of genes. In human cells, 
two forms of the estrogen receptor 
(ER) have been described to date, 
the originally described ER-α, 
encoded by a gene on chromosome 
6 1, and the more recently described 
ER-β, encoded by a gene on 
chromosome 14 2. The progesterone 
receptor (PR) also exists in more 
than one form. PR isoforms A and B 
have been well characterized 3. A 
third truncated form, PRC, has also 
been reported 4. PR is different than 
ER in that the same gene on 
chromosome 11 encodes all of the 
PR variants described to date. 
 
The existence of ER was first 
deduced in the late 1950’s, but ER 
was not cloned and sequenced until 
1984 5. Interestingly, and quite 
pertinent to the discussion of mutant 
ERs below, the receptor as originally 
cloned and sequenced contained a 
point mutation that substantially 
reduced its activity compared to the 
wild type (wt) receptor, a finding 
which will be expanded upon below. 
Much more recently, a second ER 
was identified 2 and is referred to as 
ER-β; consequently the originally 
identified receptor is now referred to 
as ER-α. 
 
Details of Steroid Receptor 
Structure and Function 
 
ER and PR are members of a large 
class of receptors generically 
referred to as the steroid-thyroid 
hormone receptor superfamily. All 
members of this family share certain 
common structural features. They 
are all encoded by multi-exon genes 
that produce proteins containing 
several functional domains, as 
depicted in Figure 1 using PR as an 
example. The domains of the steroid 
receptors are labeled A through F 
from the N to the C terminus, and 
were originally defined by separation 
by proteolytic cleavage, but have 
now been more rigorously 
characterized via molecular and 
biochemical methods. Although 
specific details vary to some degree 
from receptor to receptor, several 
common functional themes can be 
mapped to the various regions. The 
A and B domains participate in 
protein-protein interactions with 
additional modulator proteins that 
mediate the transcriptional activation 
of target genes. The C region 
contains the DNA binding domain, 
which has two zinc-finger motifs that 
serve to anchor the receptor to 
specific DNA recognition sequences. 
The C region also contains the 
nuclear localization sequence (NLS) 
necessary for shuttling the receptor 
into the nucleus. Region D consists 
of a relatively unstructured hinge 
region between the hydrophilic DNA 
binding domain and the more 
hydrophobic region E. Region E itself 
contains the ligand binding pocket 
and also contains sequences that 
interact with additional modulator 
proteins, allowing the receptor to 




Proceedings in Obstetrics and Gynecology, 2011 July;2(1):1 
 




Figure 1.  
 
Functional domains of progesterone receptor A and B. The A and B isoforms of PR arise 
from alternative promoters from the same gene. The B isoform (upper figure) is identical in 
sequence to the A isoform (lower figure) with the exception of the first 164 amino acids at the N-
terminus, termed the B upstream segment (BUS). The domains are divided into functional units 
A-E. IF = an inhibitory function area unmasked by the absence of BUS; DBD = the DNA binding 
domain; CoR = a hinge region known to bind to receptor co-modulators; LBD = the ligand 
(hormone) binding domain. AF 1-3 = activation functions required for gene transactivation and 
protein/protein interactions. The numbers noted above indicate the amino acids. 
 
Steroid receptors function primarily 
as dimers, and sequences within 
regions C and E provide the 
interface for dimer formation. In the 
absence of hormone, receptors are 
monomers associated with 
chaperone proteins such as heat-
shock protein 90 as well as other 
factors; upon binding hormone, the 
receptor dissociates from its 
chaperones and dimerizes with 
another receptor molecule 6. This 
paired, ligand-bound receptor then 
binds to DNA, interacts with other 
accessory proteins that modulate its 
function (described in more detail in 
subsequent sections) and exerts its 





Estrogen Receptor Variants 
 
ER-α follows the basic structural 
outline of the steroid thyroid 
hormone receptor superfamily 
described above. ER stimulates 
transcription by means of distinct 
functions, performed by intra-
receptor sequences, including a 
transcription activation function in the 
DNA binding region and two 
nonacidic transcription activation 
functions, TAF1 in the A/B region 
and TAF2 in the E/F region. ER-β is 
structured similarly, with the 
following regional homology to ER 
alpha A/B: 20%, C: 95% and E: 60% 
2.  
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Some of the first indications that 
variant or mutant receptors exist 
came from breast and endometrial 
cancers. In the breast, many tumors 
initially express ER at levels above 
those found in non-malignant breast 
cells 7, and while ER expression is a 
marker for well-differentiated breast 
cancers, the levels in many tumors 
are inappropriately high. Since 
estrogen induces PR expression in 
the breast 8, PR levels generally 
correlate with ER and are a good 
prognostic factor for tumor 
responsiveness to antiestrogen 
therapy. However, some tumors are 
ER+/PR- or ER-/PR+. These 
phenotypes have been explained on 
the basis of mutant ER, and provided 
the first hints that abnormal ER may 
be present in breast tumors 9. For an 
ER+/PR- tumor, it is predicted that 
the pathways leading to PR 
activation by ER are interrupted. One 
mechanism of interruption is a 
mutation in ER that prevents 
transactivation of the PR gene. For 
ER-/PR+ tumors, another type of ER 
mutant is predicted, namely, a 
constitutively active ER that can 
activate gene transcription but has a 
mutation in the hormone binding 
domain. Such a receptor would not 
be recognized by ligand binding 
assays, and the tumor would be 
considered ER negative. 
 
In the endometrium, ER and PR are 
induced in the first half of the cycle 
and down-regulated in the luteal 
phase. Over 95% of all endometrial 
cancers express ER, and similar to 
early breast cancers, the 
concentration of ER is high - perhaps 
abnormally high. ER is a marker for 
differentiation, and PR is generally, 
but not always, present. Rarely, 
ER+/PR- tumors are identified. Such 
tumors tend to have a poor 
prognosis and do not respond to 
progestin therapy 3. 
 
Numerous reports of mutations 
leading to variant ER messages 
have appeared in the literature over 
the past two decades. The majority 
of these variants have been 
observed in ER-α; however, in time, 
it is likely that variant forms of ER-β 
will also be discovered. For example, 
the possibility that a longer form of 
ER-β exists has been suggested 10. 
Also, although not strictly related to a 
discussion of variant receptors, there 
has been one report suggesting that 
the ratio of ER-α to ER-β may play a 
role in cancer development. In this 
study, it was found that ER positive 
tumors had a significantly higher ER-
α to ER-β ratio than did adjacent 
normal tissue, but there was no 
difference in the ratio for ER 
negative tumors compared to 
adjacent normal cells 10.  
 
ER-α is expressed in the female and 
male reproductive tracts, breast, 
brain, bone, liver, vasculature, heart, 
kidneys, adrenals, and possibly other 
sites. ER-α was originally cloned 
from the prostate gland in rats 2, but 
is now known to be widely expressed 
in humans and rodents. ER-β is 
present at the mRNA level in many 
tissues including the male and 
female reproductive tracts, brain, 
bladder, breast, heart 11, and 
interestingly, in the ER-α knock-out 
(ERKO) mouse model described by 
Lubahn and colleagues 12. Not 
surprisingly, the ratios of ER-α to 
ER-β vary between organs. ER-α 
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predominates in the rat uterus and in 
endometrial cancer cells and induces 
numerous growth-promoting genes 2. 
ER-α also predominates in the 
stromal cells of the prostate; 
however, ER-β is more highly 
expressed in the epithelial cells of 
the prostate. In the cerebral cortex 
and the pituitary, the distribution of 
the two ERs is similar, but in the rat 
hypothalamus, cerebellum, brain 
stem, and spinal cord, ER-β is the 
most highly expressed.  
 
As mentioned previously, ER-α and 
ER-β are not splice variants, but are 
unique genes mapping to different 
chromosomes. Both receptors bind 
estrogens with approximately equal 
affinity, and they both bind 
antiestrogens 4-OH-tamoxifen, 
tamoxifen, and ICI 164384 11. Both 
receptors also are likely to bind to 
the same promoter sequences, 
termed estrogen response elements, 
since their DBD regions differ by only 
one amino acid. However, with 
significant dimorphism in the A/B 
domains of the N-termini of ER-α 
and ER-β, transcriptional activation 
of individual genes is likely to differ 
significantly between the two ERs 13. 
The A/B domain functions in 
intermolecular protein/protein 
interactions as well as intramolecular 
interactions with the C-terminus. 
These interactions have significant 
effects on the ability of receptor 
dimers to induce transcription. The 
transcriptionally active form of ER is 
a ligand-bound dimer; ER-α and ER-
β can form homo- and heterodimers 
(ER-α/ER-α, ER-α/ER-β, ER-β/ER-
β). The propensity of ER-α and ER-β 
to heterodimerize presents additional 
consequences for differential gene 
activation 14. To date, very little is yet 
known about ER-β with respect to 
what genes are differentially 
regulated compared to ER-α, or the 
functional differences of the different 
dimeric forms. In addition, antibodies 
that distinguish between the two ER 
forms have only recently become 
available. Studies of ERα compared 
to ERβ expression in endometrial 
tumors are just now being 
performed.  
 
Progesterone Receptor Isoforms 
 
Two isoforms of PR, PRA and PRB, 
are expressed in humans, and both 
are likely to be required for 
endometrial differentiation. PRA and 
PRB are located on the same gene 
and are encoded from alternative 
promoters to ultimately generate a 
90 kDa or 120 kDa protein, 
respectively. Homo- or 
heterodimerization of PRA and PRB 
is required to form the functional 
transcription factor unit on DNA. 
Studies by Clarke and colleagues 
have demonstrated both isoforms 
are expressed in the glands and the 
stroma, though at different ratios: 
PRA may be the primary form 
expressed in the stroma, and PRB is 
the dominant form in the glandular 
epithelium 15. The amino acid 
sequences of the isoforms are 
identical except that PRB has a 
longer 165 residue N-terminus, 
which contains a third activation 
function (AF-3, Figure 1). The 
conserved sequences down-stream 
from the N-terminus of PRB include 
a DNA binding domain (DBD), a 
hinge region with the nuclear 
localization sequence (NLS), a 
region to which co-modulators (Co-
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R) bind, and the ligand binding 
domain (LBD) with activation 
function-2 (AF-2).   
 
The unique N-terminus of PRB with 
AF-3 encoded therein has conferred 
different functional characteristics on 
the isoforms: PRB is a stronger 
transcriptional activator of many 
genes compared to PRA 16-18, but 
PRA apparently counters estrogen 
action directly by inhibiting ER 
function in a dominant negative 
manner 17. In endometrial cancer cell 
lines, both isoforms function to 
enhance differentiation, with PRA 
inducing cell senescence and PRB 
inducing a secretory phenotype. 
While expression of either isoform in 
endometrial cancer cells augments 
sensitivity to apoptosis and inhibition 
of the G1 to S cell cycle transition 19, 
with respect to growth inhibition, 
PRB appears to be the dominant 
controller of growth of human 
endometrial cancer cells when 
cultured in vitro 20. Of note, PRB 
expression is undetectable in the 
poorly differentiated endometrial 
cancer cell lines (e.g., Hec50 and 
KLE), identifying a role for PRB in 
maintaining a differentiated 
phenotype 17, 18. In accord with that 
hypothesis, it has been shown that 
PRA and PRB or only PRA is 
downregulated in endometrial 
cancers 21, 22. Several animal models 
have been created to identify the role 
of PRA and PRB in endometrial 
cancer 3, though the data are 
somewhat conflicting with the 
function of PRB in human 
endometrial cancer cell lines. For 
example, progesterone activation of 
PRB in the mice deficient in PRA 
promotes proliferation of endometrial 
tissue 23, which results in significant 
endometrial hyperplasia in female 
PRA-/- mice knock-out mice 24. These 
studies are of interest but should be 
interpreted with caution given the 
differences between rodents and 
humans: while progesterone does 
induce endometrial hyperplasia in 
PRA-/- mice, these animals do not 
develop carcinoma in situ. However, 
it cannot be completely ruled out that 
PRB exerts proliferative effects in the 
human endometrium. 
 
Further complicating the field, one 
report now indicates that 
commercially available antibodies 
against PRA/B may not bind the two 
isoforms with equal affinity in 
immunohistochemical samples, 
though the antibodies do have equal 
affinity for denatured protein (e.g., as 
assessed by western blotting). 
Moreover, many PR antibodies only 
recognize PRA and not PRB though 
the epitope is in a conserved region 
25, which suggests that earlier 
immunohistochemical studies of PR 
expression may have 
underestimated PRB levels 21. 
Hence, future studies are critical to 
determine how differential 
expression of PR receptor isoforms 
impacts clinical outcome. These 
studies are necessary to fully 
evaluate the feasibility of hormone 
therapy as a treatment strategy for 
endometrial cancer.  
 
Androgen Receptor Variants 
 
Although currently in debate in the 
literature 26, androgen receptors 
(ARs) have been reported to be 
expressed in two isoforms, the 
longer B protein (110 kD) and the 
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shorter A protein (87 kD), the 
product of an N-terminus truncation 
27. In vitro data suggest that the two 
forms are functionally equivalent in 
cell lines with respect to activation by 
androgens and anti-androgens on 
synthetic DNA promoters, but 
additional data on the gene 
expression profiles induced by the 
two forms would be helpful to 
confirm these initial findings 28. 
Alterations in the expression of AR 
isoforms have been reported in colon 
cancer 29, with the A isoform 
predominating over the B and raising 
the possibility that, like PR, AR 
isoform expression may be disturbed 
in the process of carcinogenesis. 
 
Glucocorticoid Receptor Isoforms 
 
Glucocorticoid receptors (GRs) are 
transcribed and translated into a 
number of isoforms. Therefore, GRs, 
like PRs and ARs, exist in at least 
two isoforms as a result of 
alternative transcription and 
translation from the same gene. The 
two principal proteins that result are 
the 94 kD GRA and the 91 kD GRB. 
Studies now indicate that the two 
isoforms differ in their ability to 
activate transcription on consensus 
glucocorticoid DNA response 
elements: the shorter isoform, GRB, 
is twice as efficient at inducing 
transcription as the longer GRA 30. 
Interestingly, the consensus 
sequences for the PR and GR DNA 
response elements are identical, 
though the actual sequences in 
hormone responsive gene promoters 
vary and may direct whether the 
gene is controlled by progestins 
through PRs or by glucocorticoids 
through GRs 31. Interestingly, the 
shorter GRB resides in the nucleus 
in the absence of ligand, whereas 
GRA is normally in the cytoplasm 
and requires ligand for nuclear 
localization 30. This differential 
localization in the absence of ligand 
is reminiscent of observations in 
endometrial cancer cells, where the 
shorter form of PR, PRA, is nuclear 
even in the absence of ligand 
(Leslie, unpublished observations), 
whereas the longer isoform, PRB, 
requires ligand or phosphorylation by 
MAP kinase for nuclear localization. 
The similarities between PR and GR 
isoforms are in distinction to the ER 
isoforms. ER-α and -β are 
transcribed from different genes and 
diverge significantly in structure over 
much of the molecules.  
 
Activity of Steroid Receptors 
 
Over the past two decades, the 
efforts of many laboratories have 
been focused on identifying the 
mechanism(s) by which steroid 
receptors exert their transcriptional 
regulatory effects. Steroid receptors 
bind to specific short DNA 
sequences termed enhancer 
elements, which are found upstream 
of regulated genes. However, simply 
binding to DNA is insufficient for 
steroid receptors to carry out their 
function. Critical to the regulation of 
steroid response is the ability of the 
receptor to interact with a wide array 
of transcriptional co-factors. Some of 
these co-factors serve to enhance 
the activity of the receptor whereas 
others blunt it, either in the liganded 
state or when the receptor is 
unoccupied. The inhibitory function 
of co-factors ensures that the steroid 
receptor does not inappropriately 
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activate transcription in the absence 
of hormone. Prevailing evidence 
indicates that the cell and tissue 
specific effects of ER (and indeed, all 
receptors) are due to the different of 
array of activating and repressing 
cofactors present in a given cell. 
 
Estrogen, progesterone, 
glucocorticoids, and androgens act 
via genomic and non-genomic 
pathways to control cell function and 
proliferation. The genomic pathway 
leads directly to the transcription of 
hormone-dependent genes and is 
the principal and best-studied mode 
of action. Gene expression profiling 
in response to steroid hormones 
through their cognate receptors has 
provided new information on the 
large number of pathways controlled 
by these factors. Cytokines, cell 
adhesion molecules, growth factors 
and their receptors, signaling 
molecules, pro- and anti-apoptotic 
factors, DNA binding proteins, 
enzymes, other classes of 
transcription factors, and cell cycle 
regulators are now known to be 
under hormonal control 19, 20, 31-41. 
Hormone-dependent gene 
transcription results from the binding 
of the steroid hormones as ligands to 
specific nuclear receptors 42. ER, 
PR, glucocorticoid receptor (GR), 
and androgen receptor (AR) are 
members of the super-family of 
steroid and thyroid hormone 
receptors 43. They are best 
characterized as nuclear 
transcription factors responsible for 
binding to DNA, recruiting a protein 
complex of co-modulators as well as 
the basal transcriptional unit, and 
initiating the expression of hormone-
dependent proteins 44.  
Varying degrees of conservation 
exist among the functional domains 
of the receptors, as shown for PR in 
Figure 1. The N-termial A/B domain 
is not highly conserved but contains 
important activation functions (AFs) 
responsible for protein-protein 
interactions with co-activators and 
co-repressors that impart a positive 
or a negative transcriptional 
conformation on the receptor 
complex 45. In contrast, the DBD is 
the most highly conserved region of 
the receptor family. This domain 
contains numerous basic amino 
acids arranged into two zinc fingers 
responsible for recognizing and 
binding to specific DNA response 
elements in the promoters of 
hormone-dependent genes. The 
LBD, located near the carboxyl 
terminus, is fairly heterogeneous 
among family members to allow 
different ligands to bind to the 
otherwise similar family members. In 
addition, the LBD contains a 
hormone-dependent AF involved in 
protein-protein interactions. 
 
Non-genomic effects of steroid 
hormones  
 
Non-genomic functions within the 
cytosol and at the cell membrane are 
also attributed to steroid hormones. 
The best studied non-genomic 
effects thus far is the activity of 
estrogen through ERs and other 
membrane and cytosolic receptors 
46, but ARs are also reported to be 
present in the membrane fraction 47, 
indicating that the findings for 
estrogen may also relate to other 
steroid hormones. Recent evidence 
suggests that there are at least two 
non-genomic pathways by which 
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estrogen acts in the membrane. 
First, the classic ER-α protein can 
localize to the membrane as well as 
the nucleus. These data suggest that 
estrogens activate ERs at the 
membrane, resulting in rapid cellular 
effects that may control ion fluxes 
and signaling pathways 48, 49. 
Second, it has been reported that 
estrogens, and to a lesser extent, 
partial estrogens and anti-estrogens 
such as tamoxifen and ICI 182780, 
respectively, can bind a novel 
membrane G-protein receptor, 
GPR30 50, 51. Interestingly, the 
transcription of GPR30 is under the 
control of progesterone in breast 
cancer cells, and is involved in 
progesterone as well as estrogen 
control of cell proliferation 52-54. 
GPR30 controls the activation of the 
epidermal growth factor receptor 
(EGFR) and downstream signaling 
events including Ras 
phosphorylation 55. The effects of 
Ras activation include the 
phosphorylation of proteins, such as 
PI3 kinase, that ultimately control 
apoptosis, and others, such as MAP 
kinases, that phosphorylate and 
activate a myriad of transcription 
factors, including the hormone 
receptors themselves, members of 
the AP-1 family, and proto-
oncogenes such as c-Myc. Protein 
kinases C and A are also activated 
by non-genomic pathways of 
estrogen action, and these are 
involved in the control of intracellular 
calcium and pH 55.  
 
Membrane PRs and GRs have also 
been hypothesized to exist because 
progesterone and corticosteroids 
have a number of very rapid cellular 
effects, on the order of seconds and 
minutes, that could not occur as a 
result of transcription, which takes 
hours. A progesterone-binding 
protein distinct from the nuclear 
receptor has been identified in 
porcine vascular smooth muscle 
cells 56. Most recently, a new family 
of membrane progesterone binding 
proteins with similarities to G protein-
coupled receptors has been cloned 
from the spotted seatrout, the 
mouse, pig, zebrafish, Xenopus, and 
the human 57, 58. These bind 
progestins with high affinity and are 
saturable, indicating their function as 
specific receptors through which 
progestins may exert rapid 
membrane and cytoplasmic effects. 
Classic GRs have been identified in 
the membranes of lymphoma cells 
59, and cytoplasmic GRs and PRs 
may cross talk with signal 
transduction pathways that could 
initiate or enhance responses in 
conjunction with membrane bound 
growth factor receptors or G-protein 
receptors. Both GRs and PRs shuttle 
in and out of the nucleus, and PRB, 
for example, exists mainly in the 
cytoplasm in the absence of ligand in 
breast cancer cells 60 and in 
endometrial cancer cells (Leslie, 
unpublished observations). PRB is 
driven into the nucleus in the 
presence of progesterone or EGF by 
two distinct mechanisms, indicating 
that growth factor signaling as well 
as hormonal ligands may activate 
hormone receptors and set the stage 
for steroid receptor activity in the 
nucleus 60. 
 
Hence, the understanding of 
hormone effects now encompasses 
the nuclear receptors as activators of 
transcription as classically described, 
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as well as cytosolic and membrane 
receptors (membrane-bound ERs, 
ARs, GRs, GPR30, G-protein like 
receptors for progesterone, and 
possibly others) through which 
moment by moment ion fluxes, 
signal transduction pathways, 
apoptosis, as well as the activity of 
other transcription factors are 
controlled. 
 
Expression of hormone receptors 
in the normal endometrium  
 
With respect to endometrial 
proliferation and differentiation, by 
far the best- studied steroid 
hormones are estrogen and 
progesterone. ERs are expressed in 
both the glandular eplithelium and 
the stroma in increasing 
concentrations as the proliferative 
phase of the cycle progresses. At 
ovulation, ERs are down-regulated in 
response to progesterone production 
from the ovary. PRs are also induced 
in increasing concentrations during 
the proliferative phase, in part due to 
rising estradiol levels that induce 
PRs through ERs. The A isoform of 
PR predominates over the B isoform 
throughout the menstrual cycle, 
particularly in the stroma 61. 
However, PRBs are induced more 
dramatically by estradiol, particularly 
in the glandular epithelium. During 
the secretory phase of the menstrual 
cycle, ERs and PRs are gradually 
down-regulated in the glandular 
epithelium, but PRs are still 
expressed in the stroma where 
progesterone is critical for ongoing 
proliferation and the secretory 
response.  
 
GRs are expressed in human and 
rodent endometrium, and ARs have 
been identified in the human and 
rodent ovary and uterus 62. ARs are 
induced by estrogen and down-
regulated by testosterone 63, though 
others have suggested that estradiol 
plus testosterone most strongly 
induces AR 64. Progesterone has 
also been implicated in the induction 
of AR in the endometrium 65, most 
likely when it is combined with 
estrogen 64. ARs are present in the 
glandular epithelium and to a greater 
extent in the stroma of the 
endometrium. The receptors are 
induced during the proliferative 
phase of the cycle, present in stable 
amounts during the early secretory 
phase, and lost in the late secretory 
phase of the menstrual cycle 66. 
Androgens act through ARs in the 
endometrial stroma to induce the 
expression of prolactin, a marker for 
endometrial differentiation, which is 
also induced by progesterone 
through PRs 67. Androgen also 
inhibits the effects of estrogen, 
limiting proliferation in the epithelium 
and the stroma 68, and ARs are 
expressed in 40 to 88 percent of 
endometrial cancers 69. A careful 
balance of hormone expression in 
the endometrium at the distinct 
stages of the menstrual cycle is 
critical to prevent oncogenesis.   
 
Cross-talk between the 
endometrial glands and stroma 
 
The endometrium is composed of 
two cell types, the glandular 
epithelium and the stroma. 
Endometrial cancers arise most 
commonly in the glandular 
epithelium.  However, the glands and 
Proceedings in Obstetrics and Gynecology, 2011 July;2 (1):1 
 
Hormones and Receptors in Endometrial Cancer  11 
 
stroma communicate directly, and it 
is likely that abnormal interactions 
between the two tissues may occur 
in the process of endometrial 
carcinogenesis 70. The epithelial 
glands and the stroma both express 
ERs and PRs, and expression in 
both tissue types is likely to be 
necessary to induce normal growth 
and differentiation of the glandular 
epithelium. For example, 
reconstitution experiments using 
stromal and epithelial cells from 
estrogen receptor knock-out (ERKO) 
and normal mice demonstrate that 
epithelial cell proliferation in the 
mouse is mediated via ER action 
from the stroma 70-72. In addition, 
stromal PR levels are much higher 
than epithelial levels at the time of 
implantation, making it clear that 
progesterone’s effects at critical 
stages in endometrial function are 
mediated through the stroma 73. It is 
predicted that some aspects of 
epithelial cell differentiation in 
response to progesterone may be 
mediated through stromal PRs 74. 
Therefore, evaluation of receptor 
expression in the stroma as well as 
the glands may provide insight into 
the process of carcinogenesis and to 
the responsiveness of the tumor to 
progestin therapy.  
 
Steroid receptor status in 
endometrial cancers 
 
Ligand binding assays for steroid 
receptors as well as 
immunohistochemistry (IHC) have 
been used to determine protein 
levels in endometrial tumors. Most 
studies from the last decade use 
IHC, which is well accepted as a 
modality to localize and semi-
quantitate ERs and PRs in paraffin-
embedded endometrial tumor 
tissues. IHC allows the evaluation of 
multiple regions of the tumor and can 
be used to distinguish ERs and PRs 
in the glands as well as the 
surrounding stroma, thereby 
providing a significant advantage 
over ligand binding assays 75.  
 
Numerous studies support the 
finding that high ER and PR levels 
are associated with a well 
differentiated tumor phenotype. Initial 
work was done by the ligand binding 
method on protein extracts from 
tumors. McCarty et al studied 58 
patients for histologic grade and 
ligand binding activity for ER and PR 
76. Eighty-five percent of the well 
differentiated lesions demonstrated 
high levels of ER and PR, whereas 
only 13% of poorly differentiated 
tumors had detectable levels of ER 
or PR.  Following 114 patients with 
endometrial cancer, Ehrlich et al 
demonstrated a reduction in PRs 
with poorly differentiated tumors as 
well as a statistical correlation 
between the response of the patient 
to progestin treatment and the 
presence of PRs 77. Improved 
response to therapy for patients with 
high ERs and PRs was also 
documented by other ligand binding 
studies 78, 79 as well as by Carcangiu 
and Chambers in some of the first 
major reports of IHC for ERs and 
PRs in endometrial cancers 80, 81. In 
these studies, receptor status was 
determined by IHC as well as by 
traditional ligand binding assays on 
183 tumor specimens. The 
correlation was very good between 
the techniques, and the best 
predictor of a good outcome was 
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high ER levels by IHC. An early 
paper that distinguished between 
hormone responsive tumors (type I) 
and non-hormone responsive tumors 
(type II) demonstrated the loss of 
PRs in type II tumors by ligand 
binding 82. Even in early stage and 
grade tumors, loss of PRs has been 
reported to be a predictor for 
adverse clinical outcome 83, 84. ER 
status by IHC was correlated with 
survival in a study of 78 cases of 
endometrial cancer 85. High PR and 
ER levels were found to be 
predictive of survival and low PR 
levels to be predictive of lymph node 
metastasis in two similar IHC studies 
from the same laboratory 86, 87. In 
spite of the apparent usefulness of 
identifying receptor status in 
endometrial tumors as a predictor of 
hormonal responsiveness and good 
clinical outcome, more recent data 
cast doubt on whether receptor 
status is an independent predictor of 
recurrence. Indeed, Fanning et al 
studied 62 endometrial cancers for 
ER, PR, p53, HER-2/neu, c-myc, 
and additional proteins considered to 
be markers for proliferation 88. They 
determined that none of the proteins 
identified by IHC were independently 
able to predict recurrence over and 
above the surgical stage and grade 
of the tumor. This suggests that 
more investigations are indicated, 
including an analysis of receptor 
isoforms, to more firmly establish the 
clinical usefulness of receptor 
identification in endometrial cancers.  
 
Clinical role of hormones in 
endometrial cancer 
 
Endometrial carcinogenesis is 
related to overexposure to estrogen 
that is not balanced by the 
differentiating effects of 
progesterone and potentially other 
steroid hormones, including 
androgens and glucocorticoids. The 
endometrium is one of the most 
estrogen sensitive tissues in the 
body and responds to estrogens with 
rapid cell growth: unopposed 
estrogen stimulation can lead to 
endometrial hyperplasia, cellular 
atypia, and endometrial cancer. 
Initial studies indicating that the 
proliferation of the endometrium was 
under hormonal control employed 
tritiated thymidine incorporation as a 
measure of DNA synthesis in animal 
models. These original data have 
now been supplemented by detailed 
investigations that show that 
estrogens act upon the endometrium 
through estrogen receptors (ERs), 
resulting in the induction of growth 
factors such as the epidermal growth 
factor (EGF) 89, its receptor (EGFR) 
90, insulin-like growth factor-1 (IGF-1) 
91, and growth-enhancing 
protooncogenes, such as c-fos and 
c-myc 92. ERs induce PRs through 
which progesterone exerts 
differentiating effects on the 
glandular epithelium and opposes 
the growth promoting effects of 
estrogen. ARs and GRs are also 
expressed in the endometrium and in 
endometrial tumors and may be 
involved in endometrial 
differentiation 93, 94.   
  
Role of estrogen in endometrial 
carcinogenesis 
 
Excess estrogen stimulation of the 
endometrium is a well-documented 
risk factor for endometrial cancer. 
Excess estrogen stimulation can be 
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the result of the exogenous 
administration of estrogen or the 
endogenous production of estrogen. 
The best known example of 
exogenous estrogen administration 
is in the form of hormone 
replacement therapies (HRT). The 
administration of conjugated equine 
estrogens unopposed by progestin 
was once common practice for 
postmenopausal symptoms. It was 
later found to be associated with a 
higher rate of endometrial cancer 
and endometrial hyperplasia. In one 
study, a year of unopposed estrogen 
therapy resulted in 20% of patients 
developing endometrial hyperplasia 
95. In a Swedish trial of low potency 
estrogen administered for the relief 
of urogenital symptoms, oral estriol 
increased the relative risk of 
endometrial cancer and atypical 
endometrial hyperplasia. The odds 
ratios for at least five years of 
estrogen therapy were 3.0 (95% 
confidence interval, 2.0-4.4) for 
cancer and 8.3 (95% confidence 
interval, 4.0-17.4) for atypical 
hyperplasia 96.  
 
The most common example of 
endogenous estrogen excess relates 
to enzymatic production within 
adipose tissue. Obese women 
demonstrate a greater capacity for 
the biochemical conversion of 
peripherally circulating 
androstenedione to estrone. It has 
been estimated that over 40% of 
endometrial cancer incidence can be 
attributed to excess body weight 97.  
A European review of 
epidemiological data concluded that 
14,000 cases of endometrial cancer 
each year can be attributed to 
obesity 98. A case-control study of 
Danish women supported this 
mechanism by showing elevated 
plasma levels of estradiol, free 
estradiol, and estrone in endometrial 
cancer patients when compared to 
control women 99. These results 
were confirmed by a more recent 
study that found significant 
elevations in the odds ratio for 
endometrial cancer in groups of 
women with the highest quartiles of 
estradiol and estrone levels 100.  
 
There is evidence that other steps in 
the estrogen pathway can alter the 
risk for endometrial cancer. An 
elevated blood level of sex hormone 
binding globulin (SHBG) was found 
to reduce the risk for endometrial 
cancer 100, 101. SHBG binds 
estrogens in the circulation and 
renders them biologically inactive, 
thereby reducing estrogen effects at 
the target tissues. The odds ratio for 
cancer when compared to controls 
was 0.46 (0.20-1.05) to 0.51 (0.27-
0.95) in these studies 100, 101. Another 
example of estrogen pathway 
alteration involves the induction of 
hepatic cytochrome P450 enzymes 
in women who smoke. The 
increased enzyme activity results in 
greater clearance of estrogens from 
the circulation and a reduction in end 
organ effect 102. Epidemiological 
studies have demonstrated a 20-
30% reduction in the risk of 
endometrial cancer in women who 
smoke 103, 104.  
 
Endogenous estrogen production 
also occurs via autonomous 
synthesis within some ovarian 
tumors. The class of tumors most 
often associated with 
hyperestrogenism is the sex-cord 
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stromal tumors. The most common 
sex-cord stromal tumor is the 
granulosa cell tumor, which occurs 
with an incidence of 0.99/100,000 
American women 105. Human ovarian 
granulosa cells are responsible for 
the production of inhibin and 
estrogen. It is this function that may 
occur autonomously in women with 
granulosa cell tumors and lead to a 
hyperestrogenic state. The classic 
symptoms associated with a 
granulosa cell tumor include 
estrogen-stimulated end organ 
effects such as premature thelarche, 
menorrhagia, and endometrial 
hyperplasia as well as endometrial 
cancer. Endometrial cancer has 
been associated with granulosa cell 
tumors in up to 10% of cases in 
published clinical reviews 105. In 
addition, Leydig cell containing 
tumors are found to produce 
testosterone. Estrone is produced by 
peripheral aromatase conversion of 
this testosterone in adipose tissues. 
Estrogen manifestations and 
endometrial cancers have been 
occasionally reported 106. 
 
A further example of endogenous 
estrogen production occurs in the 
polycystic ovarian syndrome 
(PCOS). The PCOS is recognized as 
a metabolic and endocrine alteration 
that results in, among other things, 
hyperandrogenism. The excess of 
androgens that are produced can be 
converted to estrone to produce an 
estrogen enriched environment. 
Epidemiological studies have shown 
a five-fold increase in the risk of 
endometrial cancer among patients 





The role of progesterone in the 
glandular epithelium of the 
endometrium is primarily 
antagonistic to estrogen-mediated 
cell proliferation 107. Progestin-
related effects include the induction 
of endometrial cell differentiation and 
regulation of uncontrolled 
endometrial cell growth. These 
effects have led to significant 
therapeutic uses for progestins.  
 
A consequence of the endometrium 
stabilizing effect of progestins has 
been a reduction of endometrial 
cancer in those taking progestin or 
progestin-dominant medications. An 
early epidemiological study of 
contraceptive use in Washington 
state found that the use of 
combination preparations (both 
estrogen and progestin components) 
resulted in a 50% reduction in 
endometrial cancer risk when 
compared to the general female 
population. It was additionally shown 
that the relative risk of endometrial 
cancer for women using a high-dose 
estrogen contraceptive was 7.3 (1.4-
38.8) compared to control women 
108. In the seminal investigation of 
steroid hormone use in women 
known as the CASH study, it was 
found that at least 12 months of 
combination oral contraceptive use 
resulted in an age-adjusted risk for 
endometrial cancer of 0.6 (0.3-0.9) 
relative to control women 109. The 
risk-reduction in endometrial cancer 
afforded by progestins has also been 
shown in the context of post-
menopausal HRT. In the Million 
Women Study that was undertaken 
in the United Kingdom, the use of 
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continuous combined preparations 
resulted in a relative risk of 0.71 
(0.56-0.90) for endometrial cancer 
compared to never-users of HRT 110. 
 
Progestins have found a role in the 
treatment of the premalignant 
endometrial hyperplasias as well as 
early invasive endometrial cancer. 
This therapy has mainly been 
deemed an option for either younger 
patients that desire future fertility or 
patients that are medically 
compromised. It appears that 
hyperplasia and early invasive 
carcinoma of the endometrium 
retains responsiveness to progestins 
in a significant proportion of cases. 
The largest retrospective study of 
this treatment approach found that 
complete regression occurred in 
94% of patients with atypical 
hyperplasia and 75% of patients with 
well-differentiated carcinoma. It was 
noted that nine months was the 
median length of treatment required 
to induce a remission 111. A 
retrospective review of studies using 
79 articles reported a 76% response 
rate in grade 1 endometrial cancer 
patients with a median time to 
response of 12 weeks 112. A more 
recent prospective trial of women in 
Japan using 600 mg of 
medroxyprogesterone acetate (MPA) 
daily resulted in pathologic complete 
responses for 82% of patients with 
atypical hyperplasia and 55% of 
patients with endometrial cancer 113. 
 
In patients with advanced or 
recurrent endometrial cancer, oral 
progestins such as megestrol 
acetate (MA) and MPA have been 
reported to demonstrate response 
rates around 25% 114, 115. These 
responses have predominantly 
occurred in PR-positive tumors and 
have been short-lived with median 
overall survival reaching 10.5 
months 115. The recommended dose 
for oral MPA in the treatment of 
recurrent or advanced endometrial 
cancer was concluded to be 200 mg 
per day. Higher daily doses of MPA 
failed to yield improved outcomes as 
demonstrated by the Gynecologic 
Oncology Group (GOG) study that 
compared this regimen to 1000 mg 
daily 115. The major advantage of 
progestin-based regimens has been 
their tolerability with the most 
common side effects including 
weight gain in 26% and venous 
thrombosis in 5% of patients 114. 
 
The duration of efficacy for 
progestins has been relatively short 
with progression-free intervals 
ranging from 2.5 to 8.5 months; 
longer intervals are associated with 
low grade tumors that tested positive 
for estrogen and progesterone 
receptors 116. The lack of prolonged 
responses to progestins is thought to 
involve progestin receptor 
downregulation that accompanies 
continuous progestin therapy 3.  
 
A critical question that must be 
addressed is why, unlike non-
malignant hyperplastic disorders of 
the endometrium, so many 
endometrial cancers fail to respond 
to the growth limiting effects of 
progestins. A possible explanation is 
that endometrial cancers down-
regulate PRs 117, 118, and when 
present, PRs are down-regulated by 
progestins given as therapy 119 and 
Leslie KK, unpublished 
observations). In fact, expression of 
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PRs has been positively correlated 
with a good prognosis and response 
to progestin treatment. The overall 
response rate has been reported to 
be 72% in patients with PR-rich 
tumors but only 12% in patients with 
PR-poor lesions 116. More than 90% 
of endometrial carcinomas express 
high levels of estrogen receptors 
(ERs), whereas PR levels vary.  
Even in the presence of ERs, some 
tumors do not contain PRs 120. As 
PRs are normally up-regulated by 
estrogens via ERs, this implies that 
failure to induce PRs may be a factor 
in the genesis and/or progression of 
endometrial cancer. Loss of PR 
expression is likely to be the primary 
cause of progestin resistance in 
endometrial cancer, and tumors that 
re-grow after an initial period of 
regression in response to progestin 
down-regulate PR expression 119. 
 
The known variation in PR 
expression in endometrial cancer is 
complicated by the fact that such 
tumors are extremely 
heterogeneous121, and each tumor 
may be composed of multiple sub-
populations of cells with high or low 
responsiveness to progestins 122 and 
varying levels of PR expression. 
Interestingly, tumor heterogeneity 
and response to progestins is not 
necessarily predicted by the state of 
tumor differentiation 122, so even well 
differentiated cancers are not 
predictably sensitive to progestin 
treatment. Even in cancers 
demonstrating high total PR levels, 
progestin treatment may leave small 
sub-populations of cells with low PR 
expression unaffected, leading to 
eventual treatment failures. 
 
Anti-estrogens as an endometrial 
cancer therapy 
 
Tamoxifen is a selective estrogen 
receptor modulator with both agonist 
and antagonist effects on estrogen 
receptors, depending on the tissue 
studied. It is used to advantage in 
breast cancer for its antagonistic 
effects, but is known to carry a small 
risk for the development of 
endometrial cancer 123. Tamoxifen 
demonstrated an overall response 
rate of only 10% when used as a 
single agent in patients with 
advanced or recurrent endometrial 
carcinoma 124. In light of the data 
regarding progesterone receptor 
downregulation, the GOG combined 
tamoxifen with MPA for a trial in a 
similar patient population 125. 
Patients with advanced or recurrent 
endometrial cancer were 
administered tamoxifen, 40 mg daily 
with alternating weekly cycles of 
MPA, 200 mg daily. Although a 
higher response rate of 33% was 
achieved with the combination 
therapy, the median progression free 
survival was only 3 months with an 
overall survival of 13 months 125. 
 
Aromatase inhibitors in 
endometrial cancer   
 
Aromatase inhibitors are molecules 
that block the subcutaneous 
conversion of adrenally-produced 
androstenedione into estrone. This 
leads to less estrogen stimulation of 
the tumor. The GOG studied the 
aromatase inhibitor, anastrazole, in 
23 patients with endometrial cancer 
126. Two patients showed a partial 
response (14.8%) and the overall 
survival was six months. A higher 
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percentage of high grade serous 
cancers in this study may have 
contributed to the low response rate 
and it was noted that one of the 
responses occurred in a patient with 
a PR-positive tumor. Similar results 
were also reported by Ma and 
colleagues in patients treated with 
letrozole despite the majority of 
specimens testing positive for ER 
and PR 127. The response rate was 
9.4% with a 6.7 month median 
duration of stable disease. 
Aromatase inhibitors have yet to 
prove their efficacy in the treatment 
of endometrial cancer. 
 




(GnRH) analogues stimulate the 
pituitary to produce gonadotropins, 
which subsequently leads to a 
dramatic suppression of sex steroid 
hormone production in the ovaries. 
These agents are also thought to act 
directly on GnRH receptors found in 
endometrial tumors. Small studies 
showed conflicting results with a trial 
of goserelin reporting a 35% 
response rate but a trial of leuprolide 
reporting no responders 128, 129. The 
GOG undertook to further evaluate 
the GnRH analogue goserelin 
acetate in women with recurrent 
endometrial cancer. The agent was 
deemed ineffective in this population 
due to an 11% (4-27%) response 
rate, with a median PFS of 1.9 








Over the past 30 years, we have 
gained a great appreciation for the 
role of steroid hormones in 
maintaining endometrial integrity and 
preventing development of cancer. A 
shift in the careful balance of pro-
proliferative estrogen and 
differentiating progesterone is an 
underlying cause of cancer. Despite 
this understanding, the current 
treatment strategies for endometrial 
cancer are not as effective in 
promoting disease-free survival and 
preventing recurrence as in other 
types of hormone-dependent cancer, 
such as breast and prostate cancer. 
Future therapeutic strategies for 
endometrial cancer should focus on 
ways to re-establish the hormonal 
balance.   
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